CRISPR base editing corrects sickle cell disease mutation in 90% of patients at 18-month follow-up
Long-term data from the largest base-editing trial for sickle cell disease shows durable correction of the causal mutation across the full cohort, with no off-target edits detected at current sequencing resolution. Two patients required re-treatment due to incomplete editing at initial dosing.
Sickle cell disease is caused by a single point mutation in the HBB gene: an adenine-to-thymine substitution that changes the sixth amino acid of beta-globin from glutamic acid to valine. This single change causes the hemoglobin protein to polymerize under low-oxygen conditions, distorting red blood cells into the characteristic sickle shape and triggering a cascade of pain crises, organ damage, and shortened lifespan. It's one of the most precisely characterized genetic diseases in medicine, which made it an early target for gene therapy.
CRISPR base editing is a refinement of standard CRISPR-Cas9 that can make a single nucleotide change without cutting both strands of DNA. Standard Cas9 creates double-strand breaks, which require the cell's repair machinery to fix — a process that is error-prone and can produce unintended insertions or deletions. Base editors use a modified Cas9 that nicks only one strand, combined with a deaminase enzyme that chemically converts one DNA base to another. For sickle cell disease, the correction is converting the disease-causing thymine back to an adenine — precisely the reversal of the causal mutation.
The 18-month data represents the most important follow-up timepoint for gene therapy trials, because it gives enough time to observe whether edited cells persist and whether edited stem cells have reconstituted the patient's hematopoietic system. In 90% of patients, the answer is yes: the correction persists, edited red blood cells circulate normally, and the sickle cell phenotype is suppressed.
The 10% requiring re-treatment had incomplete initial editing — their stem cell population wasn't fully corrected, and as unedited cells divided, the proportion of sickle cells rose above the threshold for symptoms. The re-treatment protocol is the same first-line edit; the goal is achieving higher editing efficiency from the outset, which is an active area of optimization.
Off-target editing — changes to genomic sequences that resemble the target site but aren't the intended correction — was undetected at current sequencing resolution. Long-term follow-up with increasingly sensitive sequencing will be essential. The broader significance is a proof of concept that precision base editing can cure a monogenic disease in humans with durability. The same approach is now in trials for beta-thalassemia and hereditary transthyretin amyloidosis.